Oral Session 1-13D Transplant Outcomes (2)

[OS1-13D-5] Impact of HSCT in patients with relapsed or refractory marginal zone lymphoma

Satoshi Yamasaki¹, Dai Chihara², Isao Yoshida³, Kyuhei Kohda⁴, Masashi Sawa⁵, Hiroatsu Ago⁶, Kazuto Togitani⁷, Yuju Ohno⁸, Junji Tanaka⁹, Takahiro Fukuda¹⁰, Yoshiko Atsuta¹¹, Junji Suzumiya¹², Ritsuro Suzuki¹² (1.Dept. Hematol, Kyushu Medical Center, Fukuoka, Japan, 2.Center for Cancer Research, NCI, NIH, Bethesda, MD, USA, 3.Dept. Hematol Oncol, Shikoku Cancer Center, Matsuyama, Japan, 4.Dept. Hematol Oncol, Asahikawa Red Cross Hospital, Asashikawa, Japan, 5.Dept. Hematol Oncol, Anjo Kosei Hospital, Anjo, Japan, 6.Dept. Hematol Oncol, Shimane Prefectural Central Hospital, Izumo, Japan, 7.Dept. Hematol and Resp Med, Kochi Medical School, Kochi, Japan, 8.Dept. Internal Med, Kitakyushu Municipal Medical Center, Kitakyushu, Japan, 9.Dept. Hematol, Tokyo Womens Medical University, Tokyo, Japan, 10.HSCT Div, National Cancer Center Hospital, Tokyo, Japan, 11.Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan, 12.Dept Oncol Hematol, Shimane University Hospital, Izumo, Japan)